Literature DB >> 7681798

Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study.

G Rindi1, O Luinetti, M Cornaggia, C Capella, E Solcia.   

Abstract

BACKGROUND: Enterochromaffinlike (ECL) cell carcinoids recently observed in rats stimulated new interest in gastric endocrine tumors arising in humans.
METHODS: Paraffin-embedded sections of 55 endocrine tumor cases were stained with H&E, mucin tests were performed, and immunoperoxidase was used for detecting endocrine markers; 23 cases were also investigated ultrastructurally.
RESULTS: Forty-five argyrophil carcinoids, 9 neuroendocrine carcinomas, and 1 gastrinoma were identified. Three clinicopathologic subtypes of carcinoids were characterized: (1) twenty-eight cases, none metastatic, arose in a background of body-fundus atrophic gastritis and hypergastrinemia; (2) seven cases, 2 locally metastatic, were associated with hypertrophic gastropathy and hypergastrinemia due to multiple endocrine neoplasia/Zollinger-Ellison syndrome; and (3) ten were sporadic cases, 7 of which were deeply invasive, 6 metastatic, and 5 histologically atypical. All carcinoids showed histochemical and ultrastructural patterns of ECL cells. The 9 neuroendocrine carcinomas, all deeply invasive and metastatic, were composed of anaplastic, small- to intermediate-sized cells with high mitotic index and focal necrosis.
CONCLUSIONS: Gastrin-promoted carcinoids represent a benign or low grade tumor disease, whereas sporadic carcinoids and neuroendocrine carcinomas are life-threatening neoplasms, independent of gastrin promotion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7681798     DOI: 10.1016/0016-5085(93)90266-f

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  156 in total

1.  Management and disease outcome of type I gastric neuroendocrine tumors: the Mount Sinai experience.

Authors:  William C Chen; Richard R P Warner; Stephen C Ward; Noam Harpaz; Celia M Divino; Steven H Itzkowitz; Michelle K Kim
Journal:  Dig Dis Sci       Date:  2014-11-16       Impact factor: 3.199

Review 2.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

3.  Mixed exocrine and endocrine carcinoma in the stomach: a case report.

Authors:  Han Hong Lee; Chan Kwon Jung; Eun Sun Jung; Kyo Young Song; Hae Myung Jeon; Cho Hyun Park
Journal:  J Gastric Cancer       Date:  2011-06-30       Impact factor: 3.720

4.  Smooth Muscle Cell Abnormalities Associated with Gastric ECL Cell Carcinoids.

Authors:  Cesare Bordi; Pietro Caruana; Tiziana D'Adda; Cinzia Azzoni
Journal:  Endocr Pathol       Date:  1995       Impact factor: 3.943

5.  79-year-old woman with forgetfulness.

Authors:  William C Palmer; Jennifer A Crozier; Olga M Petrucelli
Journal:  Mayo Clin Proc       Date:  2012-04       Impact factor: 7.616

6.  Gastric adenocarcinoma? Looks similar but behaves differently!

Authors:  Tarun Rustagi; Mridula Rai; Todd J Alekshun
Journal:  J Gastrointest Cancer       Date:  2012-03

Review 7.  Management of gastric and duodenal neuroendocrine tumors.

Authors:  Yuichi Sato; Satoru Hashimoto; Ken-Ichi Mizuno; Manabu Takeuchi; Shuji Terai
Journal:  World J Gastroenterol       Date:  2016-08-14       Impact factor: 5.742

Review 8.  [Neuroendocrine tumors of the gastrointestinal tract].

Authors:  G Klöppel
Journal:  Pathologe       Date:  2003-05-29       Impact factor: 1.011

Review 9.  Advances in the treatment of neuroendocrine tumors.

Authors:  Matthew Kulke
Journal:  Curr Treat Options Oncol       Date:  2005-09

10.  Immunohistochemical distribution of chromogranins A and B and secretogranin II in neuroendocrine tumours of the gastrointestinal tract.

Authors:  A G Fahrenkamp; C Wibbeke; G Winde; D Ofner; W Böcker; R Fischer-Colbrie; K W Schmid
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.